• Product
    Details
  • BOND® Training
    Information
  • Prescribing
    Information
  • FAQ
  • Behavior
    Bits
  • Get in Touch
  • Product Details
  • BOND® Training Information
  • Prescribing Information
  • FAQ
  • Behavior Bits
  • Get in Touch

IMPORTANT SAFETY INFORMATION: The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. Reconcile chewable tablets are contraindicated for dogs with a history of seizures or when used with MAOIs. For product label, including complete safety information, see package insert.

NADA#141-272

The information, tools and material presented on this site are provided for informational and educational purposes only. Please consult your veterinarian for an official diagnosis of canine separation anxiety and to learn more about Reconcile. Click here to read the complete terms and conditions regarding use of this website.

PRN® and Reconcile® are registered trademarks of Pegasus Laboratories, Inc.

© PRN is a registered trademark of Pegasus Laboratories, Inc.